Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine resting-state fMRI crossover study in SSRI/SNRI non-responsive major depressive disorder
NL-OMON43144Active, not recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by Sumitomo Pharma. Primary endpoints: Resting-state fMRI whole-brain connectivity, Seed-based functional connectivity and 4 more. Started Dec 2016; status: active, not recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON43144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43144.